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the CC BY-NC-ND license (http://creaAbstract One of the major challenges that clinicians face is in the difficulties of accurately
monitoring disease progression. Prostate cancer is among these diseases and greatly affects
the health of men globally. Circulating tumor cells (CTCs) are a rare population of cancer cells
that have shed from the primary tumor and entered the peripheral circulation. Not until
recently, clinical applications of CTCs have been limited to using enumeration as a prognostic
tool in Oncology. However, advances in emerging CTC technologies point toward new applica-
tions that could revolutionize the field of prostate cancer. It is now possible to study CTCs as
components of a liquid biopsy based on morphological phenotypes, biochemical analyses, and
genomic profiling. These advances allow us to gain insight into the heterogeneity and dynamics
of cancer biology and to further study the mechanisms behind the evolution of therapeutic
resistance. These recent developments utilizing CTCs for clinical applications will greatlyin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA
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CTC in prostate cancer 255impact the future of prostate cancer research and pave the way towards personalized care for
men.
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Prostate cancer (PCa) remains one of the most prevalent
cancers affecting men across the globe. In 2012, PCa was
the second most common cancer in men with more than 1.1
million new cases, accounting for around 8% of all new
cancer cases and 15% in men. It was also noted to be the
fifth prominent cause of cancer-related mortalities in men
globally with more than 307,000 deaths [1].
The understanding of PCa biology has been advanced
with tremendous amount of data from molecular studies,
generating new classification schema [2,3], and prognosti-
cation tools [4] that go beyond the Gleason grading and
TNM staging systems. It is anticipated that these advance-
ments will reshape our therapeutic approaches for PCa.
Tissue samples taken during prostatectomy and core needle
biopsies are now being utilized for molecular profiling,
driving many of these advances. These specimens provide
information representing historic and often untreated
cancers. There have also been autopsy series that have
shown a very different molecular portrait of PCa and in
particular, metastatic-castration resistant PCa (mCRPC).
Profiling from these autopsies has provided further insight
into the temporospatial heterogeneity that underlies
advanced cancer. This has raised questions about the dy-
namic and evolving biology of mCRPC in the interval be-
tween diagnosis and death, which is currently under
investigation in centers where tissue-oriented studies have
been conducted. The typical clinical practice in caring for
men with PCa has not involved routine tissue biopsies. This
poses a challenge for translational research efforts as such
material is needed to conduct molecular characterizations
over time. The challenge in obtaining metastatic tissue
samples in mCRPC mainly lies in its typically osteotropic
nature resulting in the formation of osteoblastic lesions.
The vast majority of patients are not inclined toward having
serial bone biopsies which may require specialized instru-
mentation such as drills to cut through osseous metastases.
Additionally, sampling viable tissue samples from osteo-
blastic lesions requires experienced interventional radiol-
ogists with specialized expertise in obtaining samples from
bone and other sites that are useful for analysis. Even with
the highest levels of expertise, these methods will tend to
yield usable samples in only 60%e70% of cases. Finally, the
process of removing or decalcifying pieces of bone from
biopsies or bone marrow aspirates, places relevant and
important information about the tumor at risk for loss or
deterioration.
In contrast to this, blood analysis has been a standard of
practice in this clinical setting. Clinical phlebotomy is
simple enough that frequent blood draws can be used to
measure changes in serum prostate specific antigen (PSA)
concentration. For decades, serum PSA concentration has
been utilized to monitor the therapeutic efficacy of variousinterventions including surgery, chemotherapy, androgen-
receptor (AR) inhibition, and radiotherapy. It is known,
however, that changes in PSA do not predict clinical benefit
for other types of treatments such as immunotherapy and
targeted radionuclide therapy. Decisions made solely based
on serum PSA concentration changes early on in therapy
when patients are clinically well are cautioned against in
the recommendations provided by Prostate Cancer Working
Group 3 [5]. Nonetheless, it is apparent that blood-based
observations of PCa patients can be readily obtained,
which has led to greater interest in developing similar tests
that could complement PSA measurements and overcome
some tumor biopsy limitations [6,7].
The unmet need for new blood-based tests also stems
from the restrictions in monitoring anaplastic or atypical
carcinomas in the prostate gland, which have absent or low
levels of PSA production. A distinctive feature common to
these aggressive variants, is the potential for developing
visceral metastases (VM), which often times progresses
rapidly and lead to end organ failure and death. It is widely
recognized that serum PSA measurements lacks predictive
capacity in many mCRPC cases with VM, which tend to be
less dependent on AR activation and are more resistant to
conventional AR-targeted therapies [8e10]. In addition to
this limitation, routine monitoring of metastases in soft
tissue organs is conducted far less frequently in PCa pa-
tients, which leads to later diagnoses of VM events. This is
further complicated by the observation of an increasing
incidence of VM events that coincides with the more
frequent and early use of potent AR-inhibitors [8]. Thus, a
blood-based tool capable of monitoring the behavior of
these cancers would be an ideal way to address this unmet
need.
Circulating tumor cells (CTCs) may provide an important
means of addressing the limitations facing clinicians caring
for men with PCa. CTCs are a rare population of tumor cells
that circulate in the blood stream after detaching from a
primary tumor and/or metastatic lesions. Compared to the
10 hematologic cells found in 1 mL of whole blood [9], there
are usually less than 100 CTCs found in the same blood
volume [11e13]. This creates challenges in conducting
molecular characterization of CTCs. In order to address this
issue, numerous methods and technologies have been
developed for isolating and studying CTCs. These initiatives
are uniting the basic and clinical sciences together allowing
for the possibility of real-time dynamic profiling of disease
progression and better care for PCa patients.2. Early clinical application of CTCs:
enumeration
In 2008, the FDA cleared the CellSearch System (Veridex)
for the enrichment and enumeration of CTCs in mCRPC
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blood cells based on the expression of the epithelial-cell
adhesion molecule (EpCAM) by most epithelial cells,
including malignant epithelial cells. The EpCAM-expressing
hematologic cells are fixed and then mixed with magnetic
beads conjugated with anti-EpCAM. Thus, any cell
expressing EpCAM attached to the beads could be isolated
and harvested via magnetism. The captured cells are sub-
jected to immunofluorescent antibody labeling for cyto-
keratin (CK)-8, CK-18, CK-19, and the common leukocyte
antigen (CD45), and identify CTCs as CKþ/CD45-nucleated
events.
The IMMC38 study [14] evaluated the performance of
this CTC enumeration assay in mCRPC patients starting a
new line of cytotoxic chemotherapy. Prior to starting
therapy, patients with unfavorable CTC counts (>5 CTCs/
7.5 mL) had shorter overall survival (OS) (11.5 vs. 21.7
months; hazard ratio (HR) 3.3; p < 0.0001). Post-treatment
CTC counts that were unfavorable also predicted shorter OS
(6.7e9.5 vs. 19.6e20.7 months; HR 3.6e6.5; p < 0.0001).
At baseline, patients with CTC counts, which converted
from unfavorable to favorable, had improved OS from 6.8 to
21.3 months. Patients with CTC counts that converted from
favorable to unfavorable had poorer OS than those who
remained with favorable CTC counts (9.3 vs. 26 months).
Therefore, it is shown that CTC enumeration can pro-
vide prognostic insight to disease progression in patients
and is a better predictor of OS than serum PSA changes.
While these efforts have been important in establishing
the clinical importance and utility of CTCs, the field con-
tinues to evolve with greater needs and possibilities.
Newer CTC-technologies are being developed that address
emerging concepts resulting from the evolution of tech-
nology and cancer biology creating newer applications for
CTCs in PCa.
3. New applications of emerging CTC
technologies
Improvements in CTC-capture methods have created op-
portunities to advance our understanding of dynamic can-
cer biology. Along with the constant process of shedding
and invasion/extrusion into the vasculature, CTCs exist in a
dynamic equilibrium with the underlying tumor. This asso-
ciation between tumor and CTCs may provide a minimally
invasive way of characterizing cancers and may make CTCs
an important alternate source of cellular information.
3.1. Morphologic phenotyping of CTCs
Several of the emerging CTC identification systems utilize
more advanced microscopy and imaging techniques to re-
cord variations in cellular morphology. In classical cytopa-
thology, differences in morphology are related to
functional and biological differences among cells which
make these studies informative for characterizing CTCs.
One group reported that CTCs not only range in size, but
they also form clusters ranging from 2 to 50 cells which
were shown to be precursors of metastases in breast cancer
[15]. These CTC clusters were also found to contain tumor
cells mixed with not only other tumor cells but otherhematopoietic cells such as leukocytes. A retrospective
analysis was conducted by our group on a range of patients
with clinical PCa that have a variety of metastatic burdens
and disease sites. Upon analysis on the distribution of
cellular features, nuclear sizes were associated with the
behavior of mCRPC. In one particular case, the presence of
VM in mCRPC patients was associated with CTCs that have
nuclei smaller than 9 mm [16]. Several groups are now
describing variations in cellular and nuclear morphology in
CTCs using modern shape characterizations going beyond
simple diameter descriptions. As histopathology has
repeatedly linked both cellular and nuclear shape to func-
tion and biology, it is anticipated that several of these
studies will provide insight into the biology present within
the CTC compartment.
3.2. Biochemical analysis of CTCs: CTC-based
biomarkers
Molecular classification of tumors has become the focus of
strategies geared toward personalization of oncologic care.
Access to contemporary tissue with the ability to performed
repeated sampling limits the ability to conduct dynamic
classification of cancers that evolve over time and in the
face of therapy. This is particularly important in PCa where
natural histories can run as long as 10e15 years. Many have
begun to look to CTCs as a means of obtaining a liquid bi-
opsy that can yield information equivalent or possibly su-
perior to traditional core need or surgical biopsies.
An example of success in studying biology specific to
CRPC lies in the work done looking at AR splice variants.
These alterations of the AR hold functional importance has
evoked the interests of many in the field of AR biology. In
preclinical models investigating the efficacy of contempo-
rary AR-targeted therapies such as abiraterone, enzaluta-
mide, galeterone, apalutamide and others, certain AR
splice variants such as AR-V7 have been associated with
altered or diminished anti-cancer effect [17,18]. In a pro-
spective clinical study, Antonarakis et al. [19] character-
ized AR-V7 expression in CTCs from patients receiving
abiraterone and enzalutamide therapies. By using an
adapted AdnaGen assay, AR-V7 expression levels were
measured in mCRPC patients and AR-V7 expression was
found to be associated with a greater likelihood of devel-
oping AR-targeted therapy resistance. Since then, the study
has expanded to 200 patients classified as CTC (þ) or ();
and CTC (þ), AR-V7 (þ) or () [20]. The emergence of a
new CTC-based biomarker could significantly aid physicians
in selecting between taxanes [21] and AR-targeted therapy.
The AR-V7 CTC assay was part of the ARMOR study intended
to measure the activity of galeterone in an AR-V7
expressing population prospectively. This trial was closed,
however, due to poor accrual. It was hoped that this study
would prospectively validate this biomarker, but as it
stands alternative validations will be required.
The Johns Hopkins studies described above and other
studies following in their footsteps, have started to bring to
light the potential clinical applications of CTC-based bio-
markers. Among the pool of CTCs are subsets of actively
metastasizing cells that have the capacity to re-invade and
colonize secondary sites. Chu and Chung et al. [22e24]
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metastasis initiating cells (MICs), which possess the ability
to recruit and reprogram dormant cells to become active
metastasizers. These rare findings of MICs and AR-splice
variants in CTCs, point toward the need to investigate the
genomic and transcriptomic content of these cells.
Recently, many modern genomic tools have been
adapted to study CTCs. Among these techniques are next-
generation sequencing technologies which now use pico-
grams of genomic material appropriate for CTC analysis
[25]. Additionally, there are contemporary RNA character-
ization methods which include fluorescence-labeled oligo-
nucleotide hybridization [26], whole transcriptome RNA
microarrays [27], and single cell RNA sequencing [28].
Lastly, genome amplification and single cell DNA
sequencing is now possible [29,30] although it has the po-
tential for creating PCR-related errors and preferential
amplification of specific regions [31].
Despite the growing field for the biochemical analysis of
CTCs, there remains a need to determine the degree to
which CTC biology reflects the underlying tumor biology. In
one study, Magbanua et al. [32,33] demonstrated that CTCs
possess similar copy number variations (CNVs) reflective of
the primary tumor. However, CNV measurements in CTCs is
not accurate enough to provide definitive proof of biolog-
ical relatedness in disease progression. Studies have also
point towards targeted sequencing to compare single
nucleotide variances in CTCs and tumor tissues, detecting
mutations in oncogenes such as TP53 and BRAF [34,35]. Our
group set out to explore the relationship between CTCs and
tumor tissue samples by performing whole exome
sequencing on single CTCs and corresponding tissue bi-
opsies [36]. With this approach, our group [37] and Lohr
et al. [38] independently reported many genomic similar-
ities between PCa tissue samples and single CTCs.
As more biochemical features of CTCs grow, more
studies are showing strong molecular similarities between
CTCs and tumor tissues. Therefore, it is proposed that CTCs
may provide another dimension for studying cancer biology:
dynamics. The ability to obtain temporally discrete and
frequent information will pave the way for us to understand
the mechanisms underlying PCa in terms of heterogeneity
and drug resistance.
3.3. Heterogeneity and dynamic biology
Encompassing the realms of PCa and other malignancies,
heterogeneity is an indicative factor in tumor biology. This
existing diversity can be widely observed among tumor cells
(intratumoral), within tumors in a single patient (intertu-
moral) [39], and between patients (interpatient) [40,41].
The evolution of heterogeneity spans over time and phys-
ical space (temporospatial) and has been suggested to in-
fluence disease progression and promote drug resistance
[42].
Many studies of cancer biology heavily rely on tumor
specimens including multi-site sampling of fresh resected
tissues. Lesions that appear in soft tissues increase the
susceptibility of certain cancers, thus PCa and CRPC tend to
be less suitable to needle biopsies. As a result, serial liquid
biopsies will provide a novel approach to study the dynamicaspects of tumor heterogeneity. In one particular case,
transcriptomic analysis was performed in CTCs using AR
gene mutations and splicing variants, showing high degree
of heterogeneity among the cells [28].
The addition of temporal information to the relatively
rapid blood-based sampling of cancers will supplement CTC
studies and provide greater insight to the pathways
involved in the evolution of disease and resistance to
therapy. Miyamoto et al. [28] demonstrated this when they
conducted a CTC profiling study focused on the develop-
ment of resistance upon initial castration. These in-
vestigators found an association between the onset of
castration resistance with the activation of noncanonical
Wnt signaling. Analysis of serially collected CTCs in other
studies also confirm that CTC-derived biological informa-
tion vary over time [16,37,43].
4. Conclusion
In PCa, CTCs are clinically useful prognostic biomarkers for
response and benefit to therapy and may augment infor-
mation obtained from serum PSA measurements. CTC
enumeration is an important application that emerged from
the earlier and even more modern developing CTC plat-
forms. Newer technologies are capable of adding to the
information that can be obtained by further examining
CTCs utilizing methods currently used for tissue biopsies.
As the clinical care of men with PCa become more
personalized, the ability to conduct real time and dynamic
characterization of the disease will become increasingly
important. Both the advancements in the basic sciences
and the rising costs of therapies have pointed towards this
type of treatment. Thus, the access to a minimally invasive
procedure for tissue sampling may revolutionize the care of
men with PCa.
Recently, there has been a growing interest in the use of
blood components from liquid biopsies. Circulating tumor
DNA (ctDNA) extracted from cell-free plasma has been one
of the most studied components. However, the nature of
PCa suggests that DNA profiling may not provide as useful
information as it may in other mutation-derived malig-
nancies. In contrast to other common solid tumors, the DNA
mutation rate in PCa is relatively low [3,44]. SPOP has been
identified as one of the most frequently mutated genes in
PCa and still has a mutation rate under 15% [44]. However,
research on the transcriptome of PCa, particularly in
mCRPC, has shown more promising results. Thus, finding
ways of characterizing delicate and disease-related alter-
ations in RNA remain important to the field. That being
said, plasma and cellular components of blood samples are
not mutually exclusive and may serve as effective supple-
mentary tests in the future.
The future of modern oncology relies greatly on the
advancements of genomic medicine and liquid biopsies.
More notably, they are critically important in a disease such
as PCa where mortality continues to be an issue and where
current approaches fail to unite modern biology and clinical
practice. However, the timely advances of CTC isolation
technologies along with molecular profiling have demon-
strated that CTC research can merge these two disciplines
together. As a result, this could synergistically allow for
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other malignancies. By gaining insight into the changes in
biological behavior and the heterogeneity in disease pro-
gression, a physician may be better able to navigate ther-
apies and understand the emergence of therapeutic
resistance.
Newer developments in the area of CTC research in PCa
and other cancers have raised important questions and
challenges. Due to the rarity of cellular events and the
precision of measurements made, standards of collection
and analysis will need to be established. Given the wide
range of CTC-isolation approaches, it is unlikely that a
single cross-platform approach will ever be or should be
established. For the optimization of each developing plat-
form, it is important to understand the volume of blood
and/or numbers of tumor cells required to conduct com-
parisons. Moreover, the timing of blood-based biopsies most
likely need to vary with the rate of disease progression
since the frequency of sample collection may depend on
the analyte of interest and the methodology used. While
these factors may represent some of the technical issues
observed, they will not substantially hinder the progress of
this important field of biomedical research.
CTCs are now a part of a repertoire of tools used in the
standard practice of modern oncology. Clinical applications
for CTCs are now ready to go beyond enumeration and help
shape the future of cancer research and personalized
oncology. In doing so, CTC-based approaches will certainly
have a significant impact on the care of men with PCa.Conflicts of interest
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